Javascript must be enabled to continue!
A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to Omicron
View through CrossRef
AbstractCOVID-19 caused, as of September, 1rst, 2022, 599,825,400 confirmed cases, including 6,469,458 deaths. Currently used vaccines reduced severity and mortality but not virus transmission or reinfection by different strains. They are based on the Spike protein of the Wuhan reference virus, which although highly antigenic suffered many mutations in SARS-CoV-2 variants, escaping vaccine-generated immune responses. Multiepitope vaccines based on 100% conserved epitopes of multiple proteins of all SARS-CoV-2 variants, rather than a single highly mutating antigen, could offer more long-lasting protection. In this study, a multiepitope multivariant vaccine was designed using immunoinformatics and in silico approaches. It is composed of highly promiscuous and strong HLA binding CD4+ and CD8+ T cell epitopes of the S, M, N, E, ORF1ab, ORF 6 and ORF8 proteins. Based on the analysis of one genome per WHO clade, the epitopes were 100% conserved among the Wuhan-Hu1, Alpha, Beta, Gamma, Delta, Omicron, Mµ, Zeta, Lambda and R1 variants. An extended epitope-conservancy analysis performed using GISAID metadata of 3,630,666 SARS-CoV-2 genomes of these variants and the additional genomes of the Epsilon, Lota, Theta, Eta, Kappa and GH490 R clades, confirmed the high conservancy of the epitopes. All but one of the CD4 peptides showed a level of conservation greater than 97% among all genomes. All but one of the CD8 epitopes showed a level of conservation greater than 96% among all genomes, with the vast majority greater than 99%. A multiepitope and multivariant recombinant vaccine was designed and it was stable, mildly hydrophobic and non-toxic. The vaccine has good molecular docking with TLR4 and promoted, without adjuvant, strong B and Th1 memory immune responses and secretion of high levels of IL-2, IFN-γ, lower levels of IL-12, TGF-β and IL-10, and no IL-6. Experimental in vivo studies should validate the vaccine’s further use as preventive tool with cross-protective properties.
Title: A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to Omicron
Description:
AbstractCOVID-19 caused, as of September, 1rst, 2022, 599,825,400 confirmed cases, including 6,469,458 deaths.
Currently used vaccines reduced severity and mortality but not virus transmission or reinfection by different strains.
They are based on the Spike protein of the Wuhan reference virus, which although highly antigenic suffered many mutations in SARS-CoV-2 variants, escaping vaccine-generated immune responses.
Multiepitope vaccines based on 100% conserved epitopes of multiple proteins of all SARS-CoV-2 variants, rather than a single highly mutating antigen, could offer more long-lasting protection.
In this study, a multiepitope multivariant vaccine was designed using immunoinformatics and in silico approaches.
It is composed of highly promiscuous and strong HLA binding CD4+ and CD8+ T cell epitopes of the S, M, N, E, ORF1ab, ORF 6 and ORF8 proteins.
Based on the analysis of one genome per WHO clade, the epitopes were 100% conserved among the Wuhan-Hu1, Alpha, Beta, Gamma, Delta, Omicron, Mµ, Zeta, Lambda and R1 variants.
An extended epitope-conservancy analysis performed using GISAID metadata of 3,630,666 SARS-CoV-2 genomes of these variants and the additional genomes of the Epsilon, Lota, Theta, Eta, Kappa and GH490 R clades, confirmed the high conservancy of the epitopes.
All but one of the CD4 peptides showed a level of conservation greater than 97% among all genomes.
All but one of the CD8 epitopes showed a level of conservation greater than 96% among all genomes, with the vast majority greater than 99%.
A multiepitope and multivariant recombinant vaccine was designed and it was stable, mildly hydrophobic and non-toxic.
The vaccine has good molecular docking with TLR4 and promoted, without adjuvant, strong B and Th1 memory immune responses and secretion of high levels of IL-2, IFN-γ, lower levels of IL-12, TGF-β and IL-10, and no IL-6.
Experimental in vivo studies should validate the vaccine’s further use as preventive tool with cross-protective properties.
Related Results
L᾽«unilinguisme» officiel de Constantinople byzantine (VIIe-XIIe s.)
L᾽«unilinguisme» officiel de Constantinople byzantine (VIIe-XIIe s.)
<p>Νίκος Οικονομίδης</...
North Syrian Mortaria and Other Late Roman Personal and Utility Objects Bearing Inscriptions of Good Luck
North Syrian Mortaria and Other Late Roman Personal and Utility Objects Bearing Inscriptions of Good Luck
<span style="font-size: 11pt; color: black; font-family: 'Times New Roman','serif'">ΠΗΛΙΝΑ ΙΓ&Delta...
Un manoscritto equivocato del copista santo Theophilos († 1548)
Un manoscritto equivocato del copista santo Theophilos († 1548)
<p><font size="3"><span class="A1"><span style="font-family: 'Times New Roman','serif'">ΕΝΑ ΛΑΝ&...
Conserved T-cell epitopes predicted by bioinformatics in SARS-COV-2 variants
Conserved T-cell epitopes predicted by bioinformatics in SARS-COV-2 variants
Abstract
Background
Finding conservative T cell epitopes in the proteome of numerous variants of SARS-COV-2 is required to deve...
SARS-CoV-2 Spike Protein Evolution may Cause Difficulties for Vaccine
SARS-CoV-2 Spike Protein Evolution may Cause Difficulties for Vaccine
Abstract
Background: Coronavirus disease 2019 (COVID-19) poses a great threat to human health and life. We performed a bioinformatics analysis to compare the sequence, stru...
A survey and antibody test following the surge of SARS-CoV-2 Omicron infection in China
A survey and antibody test following the surge of SARS-CoV-2 Omicron infection in China
AbstractThe surge of SARS-CoV-2 Omicron infection in most Chinese residents at the end of 2022 provided a unique opportunity to understand how the immune system responds to the Omi...
Antigen evolution from D614, to G614, to Delta, and to Omicron subtype of SARS-CoV-2
Antigen evolution from D614, to G614, to Delta, and to Omicron subtype of SARS-CoV-2
Abstract
Importance: Since 2019, the antigens from Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) are keeping in evolution from initial D614, to G614, to Del...
From SARS and MERS CoVs to SARS‐CoV‐2: Moving toward more biased codon usage in viral structural and nonstructural genes
From SARS and MERS CoVs to SARS‐CoV‐2: Moving toward more biased codon usage in viral structural and nonstructural genes
AbstractBackgroundSevere acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is an emerging disease with fatal outcomes. In this study, a fundamental knowledge gap question is to...

